J. Sergi

424 total citations
13 papers, 324 citations indexed

About

J. Sergi is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, J. Sergi has authored 13 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in J. Sergi's work include Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (4 papers) and CAR-T cell therapy research (3 papers). J. Sergi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (4 papers) and CAR-T cell therapy research (3 papers). J. Sergi collaborates with scholars based in United States and Switzerland. J. Sergi's co-authors include Ronald M. Bukowski, G. Thomas Budd, Robert P. Whitehead, Phyllis J. Goodman, Bruce G. Redman, L. Bauer, E. David Crawford, James H. Finke, Barbara P. Barna and Jeannine Alexander and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

J. Sergi

13 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Sergi United States 9 219 163 78 47 44 13 324
S. Kudoh Japan 7 257 1.2× 444 2.7× 46 0.6× 38 0.8× 87 2.0× 12 578
Figlin Ra United States 8 101 0.5× 67 0.4× 91 1.2× 23 0.5× 112 2.5× 15 248
Ming Gu China 7 250 1.1× 206 1.3× 46 0.6× 23 0.5× 84 1.9× 12 381
Ignazio Martellucci Italy 11 280 1.3× 67 0.4× 110 1.4× 26 0.6× 64 1.5× 16 356
Zhongmin Maxwell Wang Australia 10 210 1.0× 117 0.7× 70 0.9× 59 1.3× 49 1.1× 17 330
Ana T. Nunes United States 11 275 1.3× 81 0.5× 70 0.9× 71 1.5× 120 2.7× 19 455
Daniele Pozzessere Italy 14 230 1.1× 103 0.6× 175 2.2× 35 0.7× 114 2.6× 24 426
Roberta Gonella Italy 10 115 0.5× 61 0.4× 36 0.5× 37 0.8× 61 1.4× 17 257
John Joseph Wright United States 8 141 0.6× 89 0.5× 81 1.0× 11 0.2× 72 1.6× 31 312
Maria Blumenstein Germany 6 205 0.9× 149 0.9× 33 0.4× 17 0.4× 40 0.9× 8 352

Countries citing papers authored by J. Sergi

Since Specialization
Citations

This map shows the geographic impact of J. Sergi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Sergi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Sergi more than expected).

Fields of papers citing papers by J. Sergi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Sergi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Sergi. The network helps show where J. Sergi may publish in the future.

Co-authorship network of co-authors of J. Sergi

This figure shows the co-authorship network connecting the top 25 collaborators of J. Sergi. A scholar is included among the top collaborators of J. Sergi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Sergi. J. Sergi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Budd, G. Thomas, Ram Ganapathi, L. Bauer, et al.. (1993). Phase I study of WR-2721 and carboplatin. European Journal of Cancer. 29(8). 1122–1127. 23 indexed citations
2.
Bukowski, Ronald M., James A. Young, Gary E. Goodman, et al.. (1993). Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma. Investigational New Drugs. 11(2-3). 211–217. 12 indexed citations
3.
Bukowski, Ronald M., et al.. (1992). A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma. Cancer. 69(4). 889–892. 15 indexed citations
4.
Budd, G. Thomas, James H. Finke, J. Sergi, et al.. (1992). Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.. Journal of Clinical Oncology. 10(5). 804–809. 32 indexed citations
5.
Bukowski, Ronald M., J. Sergi, G. Thomas Budd, et al.. (1991). Phase I Trial of Continuous Infusion Interleukin-2 and Doxorubicin in Patients with Refractory Malignancies. Journal of Immunotherapy. 10(6). 432–439. 5 indexed citations
6.
Barna, Barbara P., et al.. (1991). Immunologic Changes in Renal Cell Carcinoma Patients Receiving Gamma Interferon. Oncology. 48(6). 464–468. 3 indexed citations
7.
Bukowski, Ronald M., J. Sergi, G. Thomas Budd, et al.. (1991). Phase I trial of natural human interferon beta in metastatic malignancy.. PubMed. 51(3). 836–40. 7 indexed citations
8.
Bukowski, Ronald M., Patricia Rayman, Raymond Tubbs, et al.. (1991). Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.. PubMed. 51(16). 4199–205. 80 indexed citations
9.
Bukowski, Ronald M., Phyllis J. Goodman, E. David Crawford, et al.. (1990). Phase II Trial of High-Dose Intermittent Interleukin-2 in Metastatic Renal Cell Carcinoma: A Southwest Oncology Group Study. JNCI Journal of the National Cancer Institute. 82(2). 143–146. 76 indexed citations
10.
Barna, Barbara P., et al.. (1990). Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-alpha in patients with malignant melanoma.. PubMed. 9(3). 319–28. 9 indexed citations
11.
Bukowski, Ronald M., Sudish C. Murthy, J. Sergi, et al.. (1990). Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects.. PubMed. 9(6). 538–45. 13 indexed citations
12.
Budd, G. Thomas, Barbara P. Barna, James M. Boyett, et al.. (1989). Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.. PubMed. 49(22). 6432–6. 42 indexed citations
13.
Caulfield, Michael J., et al.. (1989). Treatment of chronic lymphocytic leukemia with an anti-idiotypic monoclonal antibody. Cleveland Clinic Journal of Medicine. 56(2). 182–188. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Kudoh Breakdown of academic impact, for papers by Figlin Ra Breakdown of academic impact, for papers by Ming Gu Breakdown of academic impact, for papers by Ignazio Martellucci Breakdown of academic impact, for papers by Zhongmin Maxwell Wang Breakdown of academic impact, for papers by Ana T. Nunes Breakdown of academic impact, for papers by Daniele Pozzessere Breakdown of academic impact, for papers by Roberta Gonella Breakdown of academic impact, for papers by John Joseph Wright Breakdown of academic impact, for papers by Maria Blumenstein
Rankless by CCL
2026